Key Takeaways
- Commissioner Martin Makary’s rejection of a proposed major FDA reorganization finally may be a step in the right direction for FDA staff after weeks of upheaval.
- Stakeholders now may begin to wonder whether agency staff can calm down and adjust to the new normal.
- Preventing further damage may not improve morale, but more importantly will not lower it further.
The end of the apparent plan for the US Food and Drug Administration to undergo another major reorganization this summer likely is a relief for...
The FDA already has been through significant disruption in the early months of the second Trump Administration, with thousands of staff served with layoff notices, and many more senior leaders...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?